A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
出版年份 2018 全文链接
标题
A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
作者
关键词
-
出版物
CELL CYCLE
Volume -, Issue -, Pages 1-10
出版商
Informa UK Limited
发表日期
2018-09-27
DOI
10.1080/15384101.2018.1515551
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
- (2018) Ernestina M. De Francesco et al. BIOCHEMICAL JOURNAL
- Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
- (2018) Marco Fiorillo et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
- (2018) Maria Peiris-Pagès et al. Oncotarget
- Intra-tumor heterogeneity from a cancer stem cell perspective
- (2017) Pramudita R. Prasetyanti et al. Molecular Cancer
- Mitochondrial biology in cancer stem cells
- (2017) Rute Loureiro et al. SEMINARS IN CANCER BIOLOGY
- Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development
- (2017) Lindsay Wilde et al. SEMINARS IN ONCOLOGY
- Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
- (2017) Federica Sotgia et al. Oncotarget
- Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
- (2017) Bela Ozsvari et al. Oncotarget
- Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
- (2017) Marco Fiorillo et al. Oncotarget
- Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
- (2017) Bela Ozsvari et al. Oncotarget
- Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
- (2017) Ernestina Marianna De Francesco et al. Oncotarget
- NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting “stemness”
- (2017) Gloria Bonuccelli et al. Oncotarget
- Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
- (2017) Ernestina Marianna De Francesco et al. Oncotarget
- Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
- (2016) Marco Fiorillo et al. Aging-US
- Hallmarks of cancer stem cell metabolism
- (2016) Patricia Sancho et al. BRITISH JOURNAL OF CANCER
- Cancer metabolism: a therapeutic perspective
- (2016) Ubaldo E. Martinez-Outschoorn et al. Nature Reviews Clinical Oncology
- Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells
- (2016) Marco Fiorillo et al. Oncotarget
- Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
- (2016) Gloria Bonuccelli et al. Oncotarget
- Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
- (2015) Elisabet Cuyàs et al. CELL CYCLE
- Clonal evolution and tumor-initiating cells: New dimensions in cancer patient treatment
- (2015) Anthony J. Apostoli et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- The metabolic landscape of cancer stem cells
- (2015) Ilaria Dando et al. IUBMB LIFE
- Endosymbiotic theories for eukaryote origin
- (2015) William F. Martin et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction
- (2015) Rebecca Lamb et al. Oncotarget
- Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
- (2015) Rebecca Lamb et al. Oncotarget
- Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
- (2015) Rebecca Lamb et al. Oncotarget
- Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
- (2015) Arianna De Luca et al. Oncotarget
- High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
- (2015) Gillian Farnie et al. Oncotarget
- Mitochondria as therapeutic targets for cancer stem cells
- (2015) In Sung Song World Journal of Stem Cells
- Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
- (2015) Rebecca Lamb et al. Oncotarget
- Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma
- (2014) Yao-An Shen et al. CELL CYCLE
- Endosymbiotic theory for organelle origins
- (2014) Verena Zimorski et al. CURRENT OPINION IN MICROBIOLOGY
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells
- (2013) S. Kalghatgi et al. Science Translational Medicine
- Cells, Stem Cells, and Cancer Stem Cells
- (2013) Cristóbal Aguilar-Gallardo et al. SEMINARS IN REPRODUCTIVE MEDICINE
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Mitochondrial Evolution
- (2012) M. W. Gray Cold Spring Harbor Perspectives in Biology
- Cells of origin in cancer
- (2011) Jane E. Visvader NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started